Klinička bolnica "Dubrava" bolnica je u Zagrebu, građevinski je druga najmodernija bolnica u državi i najmlađa klinička bolnica u kojoj se izvodi nastava za studente Medicinskog, Stomatološkog ...

During the past decade, University Hospital Dubrava conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 17 clinical trials were completed, i.e. on average, 29.3% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 11 clinical trials were completed. i.e. 64.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University Hospital Dubrava" #1 sponsor was "University Hospital Dubrava" with 22 trials, followed by "Celgene" with 5 trials sponsored, "Takeda" with 5 trials sponsored, "Galapagos NV" with 4 trials sponsored and "Janssen Research & Development, LLC" with 4 trials sponsored. Other sponsors include 39 different institutions and companies that sponsored additional 40 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University Hospital Dubrava" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator, "Boehringer Ingelheim" with 1 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 1 trials as a collaborator and "Cedars-Sinai Medical Center" with 1 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "University Hospital Dubrava" are "Crohn's Disease" (7 trials), "Crohn Disease" (5 trials), "Ulcerative Colitis" (5 trials), "Colitis, Ulcerative" (4 trials) and "Atrial Fibrillation" (3 trials). Many other conditions were trialed in "University Hospital Dubrava" in a lesser frequency.

Most popular intervention types in "University Hospital Dubrava" are "Drug" (53 trials), "Procedure" (15 trials), "Device" (10 trials), "Other" (5 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Filgotinib" (4 trials), "Ozanimod" (4 trials), "Rituximab" (4 trials) and "Guselkumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "University Hospital Dubrava" are 82 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are 30 active trials in "University Hospital Dubrava". 1 are not yet recruiting, 15 are recruiting, 11 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 41 completed trials in University Hospital Dubrava, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in University Hospital Dubrava, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 33 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 12 trials, and there were also 17 trials that are defined as “Not Applicable".